Local 12: Chemotherapy in recurrent ovarian cancer patients
UC researcher publishes New England Journal of Medicine study looking at outcomes
The five-year survival rate for ovarian cancer is only 36%, one of the worst cancer survival rates out there.
Finding the right treatments, however, is critical to changing that survival rate, according to Dr. Thomas Herzog, a professor at UC and gynecologic oncologist with UC Health. His team just released a study in the New England Journal of Medicine comparing those who just had chemotherapy with a recurrent cancer and those who had chemotherapy in addition to surgery when the cancer came back.
Featured photo courtesy of Unsplash.
Related Stories
We love ‘Lucy’ — the AI avatar redefining UC tech transfer
July 17, 2024
In a visionary leap at the University of Cincinnati, the marriage of artificial intelligence and interactive technology has birthed "Lucy," a Smarthelp AI avatar poised to revolutionize how regional industries engage with UC's tech transfer initiatives.
NIS program opens new horizons for international student
July 17, 2024
In his pursuit of physics and a taste for research, Akash Khanikor ventured from his hometown in India's Assam to the University of Cincinnati, drawn by the promise of hands-on exploration early in his undergraduate career as a NEXT Innovation Scholar.
Camp aims to empower children, teens who stutter
July 17, 2024
A one-week, evidence-based program for children and teens who stutter at the University of Cincinnati will teach kids to communicate effectively, advocate for themselves and develop confidence about their communication abilities. Camp Dream. Speak. Live., which is coming to Cincinnati for the first time July 22-26, began in 2014 at the University of Texas at Austin. The Arthur M. Blank Center for Stuttering Education and Research at UT expects to serve more than 2,000 children at camps across the United States, Africa, Asia and Europe this year.